64_CD
SHAREHOLDER_NN
INFORMATION_NOMZ
7a_CD
Substantial_NN
shareholdings_GER
The_DT
shareholdings_GER
in_PIN
the_DT
table_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
represent_VPRT
the_DT
shareholdings_GER
amounting_VBG [WZPRES]
to_PIN
3_CD
%_NN
or_CC
more_EMPH
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
of_PIN
the_DT
Company_NN
that_TSUB
had_VBD [PEAS]
been_VBN [PASS]
notified_VBN
to_PIN
the_DT
Company_NN
in_PIN
accordance_NN
with_PIN
Sections_NOMZ
198_CD
to_PIN
208_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
at_PIN
the_DT
time_NN
of_PIN
publication_NOMZ
of_PIN
the_DT
2000_CD
,_,
2001_CD
and_CC
2002_CD
Annual_JJ
Reports_NN
._.
The_DT
figures_NN
in_PIN
the_DT
columns_NN
entitled_VBN
2001_CD
Annual_JJ
Report_NN
and_CC
2000_CD
Annual_JJ
Report_NN
do_VPRT
not_XX0
necessarily_RB
represent_VB
the_DT
current_JJ
shareholdings_GER
or_CC
percentages_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
respective_JJ
shareholders_NN
._.
As_IN
at_PIN
11_CD
March_NN
2003_CD
2001_CD
Annual_JJ
Report_NN
2000_CD
Annual_JJ
Report_NN
Number_NN
of_PIN
Number_NN
of_PIN
Number_NN
of_PIN
shares_NN
held_VBN [PRIV]
Percentage_NN
shares_NN
held_VBD [PRIV]
Percentage_NN
shares_NN
held_VBD [PRIV]
Percentage_NN
1_CD
Baxter_NN
International_NN
,_,
Inc._NN
16,713,603_CD
16.87_CD
%_NN
11,746,041_CD
12.62_CD
%_NN
9,071,200_CD
10.23_CD
%_NN
Fidelity_NOMZ
Management_NOMZ
&_CC
Research_NN
Company_NN
6,010,194_CD
6.06_CD
%_NN
--_:
-_:
-_:
Barclays_NN
PLC_NN
4,950,803_CD
5.00_CD
%_NN
--_:
-_:
-_:
Morley_NN
Fund_NN
Management_NOMZ
Limited_NN
4,022,012_CD
4.06_CD
%_NN
3,650,893_CD
3.92_CD
%_NN
-_:
-_:
Legal_NN
&_CC
General_NN
Investment_NOMZ
Management_NOMZ
Limited_NN
3,067,3313.10_CD
%_NN
--_:
-_:
-_:
Philips_NN
&_CC
Drew_NN
Life_NN
Limited_NN
--_:
-_:
-_:
4,122,260_CD
4.65_CD
%_NN
Note_NN
1_CD
In_PIN
December_NN
2000_CD
,_,
Acambis_NN
entered_VBD
into_PIN
a_DT
strategic_JJ
alliance_NN
with_PIN
Baxter_NN
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
which_WDT [PIRE]
at_PIN
11_CD
March_NN
2003_CD
equity_NOMZ
subscriptions_NOMZ
of_PIN
19.9_CD
m_NN
net_NN
of_PIN
expenses_NN
had_VBD [PEAS]
been_VBN [PASS]
received_VBN
,_,
representing_VBG [PRESP]
16.7_CD
million_CD
new_JJ
ordinary_JJ
shares_NN
as_IN
shown_VBN [PRIV]
above_PLACE
._.
The_DT
remaining_VBG
subscription_NOMZ
totalling_VBG [WZPRES]
7.0_CD
m_NN
,_,
in_PIN
respect_NN
of_PIN
a_DT
further_JJ
4.6_CD
million_CD
new_JJ
shares_NN
,_,
was_VBD [PASS]
received_VBN
on_PIN
27_CD
March_NN
2003_CD
,_,
taking_VBG
Baxters_NN
holding_VBG [PRIV] [WZPRES]
to_PIN
21.3_CD
million_CD
new_JJ
ordinary_JJ
shares_NN
representing_VBG [WZPRES]
a_DT
20.6_CD
%_NN
holding_GER
at_PIN
that_DEMO
date_NN
._.
As_IN
far_PLACE
as_RB
is_VPRT [PASS]
known_VBN [PRIV]
to_PIN
the_DT
Directors_NN
,_,
the_DT
Company_NN
is_VPRT
not_XX0
directly_RB
or_CC
indirectly_RB
owned_VBN
or_CC
controlled_VBN
by_PIN
another_DT
corporation_NOMZ
or_CC
by_PIN
any_QUAN
other_JJ
government_NOMZ
and_CC
the_DT
only_DWNT
shareholder_NN
directly_RB
or_CC
indirectly_RB
owning_VBG
more_EMPH
than_PIN
10_CD
%_NN
of_PIN
the_DT
Company_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
above_PLACE
table_NN
._.
All_QUAN
shareholders_NN
have_VPRT
the_DT
same_JJ
voting_NN
rights_NN
._.
9a_CD
Nature_NN
of_PIN
trading_GER
market_NN
Comparative_JJ
market_NN
price_NN
information_NOMZ
9c_CD
Acambis_NN
shares_NN
are_VPRT [PASS]
traded_VBN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
under_IN
the_DT
symbol_NN
ACM_NN
and_CC
on_PIN
the_DT
US_FPP1
Nasdaq_NN
National_NN
Market_NN
in_PIN
the_DT
form_NN
of_PIN
ADRs_NN
under_IN
the_DT
symbol_NN
ACAM_NN
._.
The_DT
number_NN
of_PIN
outstanding_JJ
ordinary_JJ
shares_NN
of_PIN
10p_JJ
each_QUAN
at_PIN
that_DEMO
date_NN
was_VBD [BEMA]
99,101,858_CD
._.
Comparative_JJ
dividend_NN
information_NOMZ
Acambis_NN
has_VPRT [SPAU] [PEAS]
never_RB
paid_VBN
any_QUAN
cash_NN
dividends_NN
on_PIN
its_PIT
shares_NN
and_CC
does_VPRT
not_XX0
anticipate_VB [PRIV]
paying_VBG
cash_NN
dividends_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
65_CD
66_CD
SHAREHOLDER_NN
INFORMATION_NOMZ
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
The_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
of_PIN
the_DT
Company_NN
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
at_PIN
10_CD
a._NN
m._NN
on_PIN
13_CD
May_POMD
2003_CD
at_PIN
the_DT
offices_NN
of_PIN
Weil_NN
,_,
Gotshal_NN
&_CC
Manges_NN
,_,
One_CD
South_NN
Place_NN
,_,
London_NN
EC2M_NN
2WG_NN
._.
The_DT
Notice_NN
of_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
accompanies_VPRT
this_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_NN
._.
Special_JJ
business_NOMZ
The_DT
special_JJ
business_NOMZ
to_TO
be_VB [PASS]
conducted_VBN
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
AGM_NN
is_VPRT [PASS]
detailed_VBN
in_PIN
the_DT
Notice_NN
of_PIN
the_DT
AGM_NN
._.
In_CONJ
addition_NULL
to_PIN
the_DT
reappointment_NOMZ
of_PIN
LLP_NN
as_IN
auditors_NN
as_IN
discussed_VBN
below_PLACE
authority_NOMZ
is_VPRT
being_VBG [PASS]
sought_VBN
:_:
to_TO
change_VB
certain_JJ
rules_NN
within_PIN
the_DT
Acambis_NN
share_NN
option_NOMZ
and_PHC
share_NN
incentive_NN
plans_VPRT
the_DT
Share_NN
Plans_NN
._.
The_DT
Directors_NN
will_PRMD
seek_VB
approval_NN
to_TO
amend_VB
the_DT
Share_NN
Plans_NN
:_:
a_DT
to_TO
provide_VB
that_DEMO
during_PIN
the_DT
five_CD
years_NN
following_VBG [WZPRES]
the_DT
date_NN
of_PIN
the_DT
2003_CD
AGM_NN
the_DT
number_NN
of_PIN
shares_NN
which_WDT [WHSUB]
may_POMD
be_VB [PASS]
issued_VBN
in_PIN
connection_NOMZ
with_PIN
share_NN
options_NOMZ
or_CC
long-term_JJ
incentive_NN
awards_NN
may_POMD
not_XX0
exceed_VB
5_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
of_PIN
the_DT
Company_NN
in_PIN
issue_NN
from_PIN
time_NN
to_PIN
time_NN
._.
This_DEMP
will_PRMD
replace_VB
the_DT
current_JJ
dilution_NOMZ
limits_NN
applying_VBG [WZPRES]
under_IN
the_DT
Share_NN
Plans_NN
:_:
b_NN
to_TO
amend_VB
the_DT
Share_NN
Plans_NN
so_OSUB
that_NULL
the_DT
Company_NN
has_VPRT
the_DT
authority_NOMZ
to_TO
update_VB
these_DEMO
plans_NN
during_PIN
the_DT
five-year_JJ
period_NN
following_VBG [WZPRES]
the_DT
date_NN
of_PIN
the_DT
AGM_NN
:_:
and_ANDC
c_NN
such_OSUB
that_NULL
a_DT
qualifying_VBG
employee_NN
or_CC
Director_NN
may_POMD
,_,
in_PIN
any_QUAN
financial_JJ
year_NN
,_,
be_VB [PASS]
granted_VBN [SUAV]
discretionary_JJ
share_NN
options_NOMZ
over_IN
shares_NN
with_PIN
a_DT
market_NN
value_NN
,_,
as_RB
at_PIN
the_DT
date_NN
of_PIN
grant_NN
,_,
of_PIN
up_RB
to_PIN
two-times_NN
the_DT
participants_NN
base_JJ
annual_JJ
salary_NN
._.
This_DEMO
limit_NN
could_POMD
be_VB [PASS]
extended_VBN
if_COND
the_DT
participant_NN
had_VBD [PEAS]
been_VBN [PASS]
recruited_VBN
,_,
in_PIN
which_WDT [PIRE]
case_NN
the_DT
limit_NN
shall_PRMD
be_VB [BEMA]
four-times_PRED
his_TPP3
her_TPP3
base_NN
annual_JJ
salary_NN
within_PIN
12_CD
months_NN
of_PIN
joining_VBG
or_CC
,_,
exceptionally_RB
,_,
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
eighttimes_VPRT
his_TPP3
her_TPP3
base_NN
annual_JJ
salary_NN
if_COND
the_DT
participant_NN
is_VPRT [PASS]
based_VBN
in_PIN
the_DT
US_FPP1
and_PHC
forfeits_NN
vested_VBN
options_NOMZ
with_PIN
an_DT
immediate_JJ
previous_JJ
employer_NN
by_PIN
reason_NN
on_PIN
joining_VBG
Acambis_NN
:_:
to_TO
introduce_VB
a_DT
new_JJ
all-employee_JJ
share_NN
plan_NN
for_PIN
US-based_JJ
employees_NN
._.
The_DT
new_JJ
plan_NN
is_VPRT [BEMA]
similar_PRED
in_PIN
style_NN
to_PIN
the_DT
Acambis_NN
1995_CD
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
for_PIN
UK_NN
employees_NN
:_:
to_TO
give_VB
the_DT
Company_NN
the_DT
authority_NOMZ
to_TO
purchase_VB
up_RP
to_PIN
10_CD
%_NN
of_PIN
its_PIT
own_JJ
issued_VBN
ordinary_JJ
shares_NN
at_PIN
a_DT
price_NN
of_PIN
not_XX0
less_JJ
than_PIN
10_CD
pence_NN
per_PIN
share_NN
and_CC
not_XX0
more_EMPH
than_PIN
5_CD
%_NN
above_PLACE
the_DT
average_NN
of_PIN
the_DT
middle_JJ
market_NN
quotations_NOMZ
of_PIN
the_DT
Companys_NN
shares_NN
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
Daily_NN
Official_NN
List_NN
for_PIN
the_DT
five_CD
dealing_VBG
days_NN
before_IN
the_DT
purchase_NN
is_VPRT [PASS]
made_VBN
._.
This_DEMO
authority_NOMZ
shall_PRMD
expire_VB
at_PIN
the_DT
conclusion_NN
of_PIN
the_DT
Companys_NN
next_IN
AGM_NN
or_CC
15_CD
months_NN
from_PIN
the_DT
passing_GER
of_PIN
this_DEMO
resolution_NOMZ
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
earlier_TIME
:_:
and_ANDC
to_TO
disapply_VB
the_DT
statutory_JJ
pre-emption_NOMZ
rights_NN
in_PIN
respect_NN
of_PIN
the_DT
allotment_NOMZ
of_PIN
new_JJ
shares_NN
pursuant_JJ
to_PIN
rights_NN
issues_NN
or_CC
otherwise_CONJ
for_PIN
cash_NN
up_RP
to_PIN
an_DT
aggregate_JJ
nominal_JJ
value_NN
of_PIN
518,691_CD
,_,
being_VBG [PRESP] [BEMA]
5_CD
%_NN
of_PIN
the_DT
currently_RB
issues_NN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
in_PIN
accordance_NN
with_PIN
the_DT
current_JJ
guidelines_NN
of_PIN
the_DT
Investment_NOMZ
Committee_NN
of_PIN
the_DT
Association_NOMZ
of_PIN
British_NN
Insurers_NN
and_CC
the_DT
National_NN
Association_NOMZ
of_PIN
Pension_NN
Funds_NN
._.
This_DEMO
authority_NOMZ
shall_PRMD
expire_VB
at_PIN
the_DT
conclusion_NN
of_PIN
the_DT
Companys_NN
next_IN
AGM_NN
or_CC
15_CD
months_NN
from_PIN
the_DT
passing_GER
of_PIN
this_DEMO
resolution_NOMZ
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
earlier_TIME
._.
Auditors_NN
Following_VBG [WZPRES]
the_DT
conversion_NN
of_PIN
our_FPP1
auditors_NN
to_PIN
a_DT
limited_JJ
liability_NOMZ
partnership_NN
LLP_NN
from_PIN
1_CD
January_NN
2003_CD
,_,
resigned_VBD
and_CC
the_DT
Directors_NN
appointed_VBN
its_PIT
successor_NN
,_,
LLP_NN
,_,
as_IN
auditors_NN
._.
A_DT
resolution_NOMZ
to_TO
reappoint_VB
LLP_NN
as_IN
auditors_NN
to_PIN
the_DT
Company_NN
will_PRMD
be_VB [PASS]
proposed_VBN [SUAV]
at_PIN
the_DT
AGM_NN
._.
This_DEMO
authority_NOMZ
shall_PRMD
expire_VB
at_PIN
the_DT
conclusion_NN
of_PIN
the_DT
Companys_NN
next_IN
General_NN
Meeting_VBG [WZPRES]
._.
were_VBD [PASS]
appointed_VBN
as_IN
auditors_NN
of_PIN
the_DT
Company_NN
in_PIN
March_NN
2002_CD
,_,
at_PIN
which_WDT [PIRE]
time_NN
the_DT
current_JJ
audit_NN
partner_NN
was_VBD [SPAU] [PASS]
also_RB
appointed_VBN
._.
10b_JJ
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
A_NN
summary_NN
of_PIN
the_DT
principal_JJ
provisions_NN
of_PIN
the_DT
Groups_NN
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
can_POMD
be_VB [BYPA]
found_VBN [PRIV]
by_PIN
referring_VBG
to_PIN
the_DT
Registration_NOMZ
Statement_NOMZ
on_PIN
Form_NN
F-4_NN
filed_VBN [WZPAST]
with_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
in_PIN
April_NN
1999_CD
relating_VBG
to_PIN
the_DT
acquisition_NOMZ
of_PIN
Acambis_NN
Inc._NN
as_RB
well_RB
as_IN
the_DT
document_NOMZ
filed_VBN [WZPAST]
in_PIN
November_NN
2000_CD
in_PIN
relation_NOMZ
to_PIN
the_DT
proposed_VBN [SUAV]
subscription_NOMZ
by_PIN
Baxter_NN
._.
A_DT
copy_NN
of_PIN
both_DT
the_DT
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
of_PIN
the_DT
Company_NN
has_VPRT [PEAS]
been_VBN [PASS]
filed_VBN
with_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
._.
The_DT
Memorandum_NN
contains_VPRT
the_DT
fundamental_JJ
provisions_NN
of_PIN
the_DT
Companys_NN
constitution_NOMZ
._.
The_DT
Articles_NN
contain_VPRT
the_DT
rules_NN
for_PIN
the_DT
internal_JJ
management_NOMZ
and_PHC
control_NN
of_PIN
the_DT
Company_NN
._.
10h_JJ
Documents_NOMZ
on_PIN
display_NN
Certain_NN
documents_NOMZ
referred_VBD
to_PIN
in_PIN
this_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_NN
are_VPRT [BEMA]
available_PRED
for_PIN
inspection_NOMZ
at_PIN
the_DT
registered_JJ
office_NN
of_PIN
the_DT
Company_NN
._.
COMPANY_NN
INFORMATION_NOMZ
AND_PHC
ADVISERS_NN
Company_NN
Secretary_NN
,_,
registered_VBD
Announcements_NOMZ
Registrars_NN
office_NN
and_PHC
Group_NN
headquarters_NN
First_JJ
quarter_NN
results_NN
May_POMD
Capita_NN
Registrars_NN
Elizabeth_NN
Brown_NN
Second_NN
quarter_NN
interim_JJ
results_NN
September_NN
The_DT
Registry_NN
Peterhouse_NN
Technology_NN
Park_NN
Third_NN
quarter_NN
results_NN
November_NN
34_CD
Beckenham_NN
Road_NN
100_CD
Fulbourn_NN
Road_NN
Final_JJ
results_NN
March_NN
Beckenham_NN
Cambridge_NN
CB1_NN
9PT_NN
Kent_NN
BR3_NN
4TU_NN
UK_NN
Corporate_NN
advisers_NN
UK_NN
Tel_NN
:_:
44_CD
0_CD
1223 275 300_CD
Financial_NN
advisers_NN
and_PHC
stockbrokers_NN
Auditors_NN
4a_VPRT
Registered_NN
number_NN
:_:
2863682_CD
Deutsche_NN
Bank_NN
LLP_NN
Date_NN
of_PIN
incorporation_NOMZ
:_:
19_CD
October_NN
1993_CD
Winchester_NN
House_NN
Abacus_NN
House_NN
Country_NN
of_PIN
jurisdiction_NOMZ
:_:
England_NN
and_PHC
Wales_NN
1_CD
Great_NN
Winchester_NN
Street_NN
Castle_NN
Park_NN
London_NN
EC2N_NN
2DB_NN
Cambridge_NN
CB3_NN
0AN_NN
US_FPP1
operations_NOMZ
UK_NN
UK_NN
38_CD
Sidney_NN
Street_NN
Cambridge_NN
Legal_NN
advisers_NN
Massachusetts_NN
02139_CD
Weil_NN
,_,
Gotshal_NN
&_CC
Manges_NN
USA_NN
One_CD
South_NN
Place_NN
Tel_NN
:_:
1_CD
617 761 4200_CD
London_NN
EC2M_NN
2WG_NN
UK_NN
Shareholder_NN
information_NOMZ
The_DT
share_NN
price_NN
is_VPRT [BEMA]
obtainable_PRED
in_PIN
most_EMPH
UK_NN
and_PHC
US_FPP1
Patent_NN
Agents_NN
national_JJ
newspapers_NN
and_CC
on_PIN
Acambis_NN
website_NN
at_PIN
Reddie_NN
&_CC
Grose_NN
www_NN
._.
com_NN
Daedalus_NN
House_NN
Station_NOMZ
Road_NN
London_NN
Stock_NN
Exchange_NN
mnemonic_JJ
ACM_NN
Cambridge_NN
CB1_NN
2RE_NN
US_FPP1
Nasdaq_NN
National_NN
Market_NN
ticker_NN
symbol_NN
ACAM_NN
UK_NN
Reuters_NN
reference_NN
ACM_NN
._.
L_NN
Clark_NN
&_CC
Elbing_GER
LLP_NN
176_CD
Federal_NN
Street_NN
Analyst_NN
coverage_NN
of_PIN
Acambis_NN
Boston_NN
Altium_NN
Capital_NN
Massachusetts_NN
02110_CD
Cazenove_NN
USA_NN
C._NN
E._NN
Unterberg_NN
,_,
Towbin_NN
Commerzbank_NN
Bankers_NN
Credit_NN
Suisse_NN
First_NN
Boston_NN
Barclays_NN
Bank_NN
PLC_NN
Deutsche_NN
Bank_NN
Corporate_NN
Banking_GER
Evolution_NOMZ
Beeson_NN
Gregory_NN
PO_NN
Box_NN
885_CD
Goldman_NN
Sachs_NN
Mortlock_NN
House_NN
ING_NN
Barings_GER
Vision_NN
Park_NN
KBC_NN
Peel_NN
Hunt_NN
Histon_NN
Merrill_NN
Lynch_NN
Cambridge_NN
CB4_NN
9DE_NN
Nomura_NN
UK_NN
Teather_NN
&_CC
Greenwood_NN
UBS_NN
Warburg_NN
WestLB_NN
Panmure_NN
Williams_NN
fide_VBD
Bro_NN
67_CD
68_CD
INDEX_NN
Accounting_GER
policies_NN
22-24_JJ
Goodwill_NN
23_CD
,_,
27_CD
Senior_JJ
management_NOMZ
11_CD
Administrative_JJ
costs_NN
25_CD
Group_NN
Executive_NN
Committee_NN
53_CD
Share_NN
capital_NN
33-34_CD
ADR_NN
pricing_GER
65_CD
Government_NOMZ
grants_NN
23_CD
Share_NN
options_NOMZ
24_CD
,_,
33-34_CD
,_,
59-61_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
66_CD
Share_NN
pricing_GER
65_CD
Arilvax_NN
8_CD
,_,
13_CD
Health_NN
and_PHC
safety_NN
51_CD
Share_NN
register_NN
analysis_NN
64_CD
Audit_NN
Committee_NN
52_CD
H._NN
pylori_NN
9_CD
,_,
13_CD
Shareholder_NN
information_NOMZ
64-66_CD
Auditors_NN
16-17_CD
,_,
66_CD
HolaVax-ETEC_NN
9_CD
,_,
13_CD
Shareholders_NN
funds_NN
35_CD
Aventis_NN
Pasteur_NN
29-30_CD
,_,
45_CD
HolaVax-Typhoid_JJ
9_CD
,_,
13_CD
Smallpox_NN
2-3_CD
,_,
6-8_CD
,_,
12-13_CD
Staff_NN
costs_NN
26_CD
Balance_NN
sheets_NN
19_CD
,_,
20_CD
Independent_NN
auditors_NN
report_VPRT [PUBV]
16-17_CD
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
18_CD
Baxter_NN
7_CD
,_,
12_CD
,_,
45_CD
Interest_NN
25_CD
Stock_NN
23_CD
,_,
30_CD
Berna_NN
Biotech_NN
13_CD
Internal_NN
controls_NN
53_CD
Stock_NN
options_NOMZ
see_VPRT [PRIV]
Share_NN
options_NOMZ
Board_NN
of_PIN
Directors_NN
10-11_CD
,_,
49_CD
,_,
50_CD
,_,
52_CD
Investments_NOMZ
23_CD
,_,
28-30_CD
Strategy_NN
6-9_CD
Subsidiaries_NN
28_CD
Capital_NN
expenditure_NN
15_CD
Japanese_JJ
encephalitis_NN
Substantial_JJ
shareholdings_GER
64_CD
Cash_NN
15_CD
see_VPRT [PRIV]
ChimeriVax-JE_NN
Summarised_NN
Group_NN
statements_NOMZ
48-49_CD
Cash_NN
flow_NN
21_CD
,_,
40-41_CD
Joint_NN
venture_NN
23_CD
,_,
29-30_CD
,_,
45_CD
CDC_NN
44-45_CD
Taxation_NOMZ
15_CD
,_,
23_CD
,_,
26_CD
,_,
46_CD
Chairmans_NN
statement_NOMZ
1_CD
Leases_VPRT
24_CD
,_,
31_CD
,_,
33_CD
Trade_NN
investments_NOMZ
29_CD
Charitable_JJ
donations_NOMZ
51_CD
Trading_GER
results_NN
14-15_CD
ChimeriVax-Dengue_NN
13_CD
Manufacturing_GER
4-5_CD
,_,
14-15_CD
Travel_NN
vaccines_NN
8-9_CD
ChimeriVax-JE_NN
8-9_CD
,_,
13_CD
MD&A_NN
42-47_CD
ChimeriVax-West_NN
Nile_NN
9_CD
,_,
13_CD
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
66_CD
US_FPP1
GAAP_NN
reconciliation_NOMZ
37-42_CD
C._NN
difficile_NN
9_CD
,_,
13_CD
MVA_NN
3_CD
,_,
7_CD
,_,
8_CD
,_,
12-13_CD
Clinical_JJ
operations_NOMZ
4_CD
VIG_NN
3_CD
,_,
8_CD
,_,
12_CD
Collaboration_NOMZ
agreements_NOMZ
44-46_CD
Nominations_NOMZ
Committee_NN
53_CD
Company_NN
information_NOMZ
and_PHC
advisers_NN
67_CD
Notes_NN
to_PIN
Group_NN
financial_JJ
statements_NOMZ
22-42_JJ
West_NN
Nile_NN
virus_NN
9_CD
,_,
13_CD
Corporate_JJ
governance_NN
statement_NOMZ
52-55_CD
Corporate_NN
social_JJ
responsibility_NOMZ
11_CD
,_,
51_CD
Operating_GER
review_NN
12-13_CD
Cost_NN
of_PIN
sales_NN
14_CD
,_,
22_CD
Organisational_NN
structure_NN
28_CD
Abbreviations_NOMZ
used_VBN [WZPAST]
in_PIN
this_DEMO
document_NOMZ
Creditors_NN
31_CD
Product_NN
update_VPRT
12-13_CD
ADR_NN
American_NN
Depositary_NN
Receipt_NN
Debtors_NN
30_CD
Profit_NN
and_PHC
loss_NN
account_NN
18_CD
APB_NN
Accounting_GER
Principles_NN
Board_NN
Directors_NN
interests_NN
51_CD
,_,
59_CD
Pensions_NN
23_CD
,_,
37_CD
,_,
57_CD
,_,
58_CD
BIA_NN
BioIndustry_NN
Association_NOMZ
Directors_NN
remuneration_VPRT
26_CD
,_,
58_CD
Political_JJ
donations_NOMZ
51_CD
CDC_NN
US_FPP1
Centers_NN
for_PIN
Disease_NN
Control_NN
and_PHC
Directors_NN
report_VPRT [PUBV]
51_CD
Post_NN
balance_NN
sheet_NN
events_NN
37_CD
Prevention_NOMZ
Directors_NN
responsibilities_NOMZ
16_CD
Property_NN
47_CD
EITF_NN
Emerging_VBG [WZPRES]
Issues_NN
Task_NN
Force_NN
Discontinued_NN
operations_NOMZ
25_CD
FASB_NN
Financial_NN
Accounting_GER
Standards_NN
Board_NN
Dividends_NN
51_CD
R&D_NN
3_CD
,_,
12-13_CD
FDA_NN
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
37-42_CD
FIN_NN
FASB_NN
Interpretation_NOMZ
Number_NN
Earnings_GER
per_PIN
share_NN
27_CD
Registrars_NN
67_CD
FRS_NN
Financial_NN
Reporting_GER
Standard_NN
Employees_NN
15_CD
,_,
26_CD
,_,
51_CD
Related_VBN
party_NN
transactions_NOMZ
37_CD
R&DR_NN
esearch_NN
and_PHC
development_NOMZ
Environment_NOMZ
51_CD
Remuneration_NOMZ
Committee_NN
52_CD
,_,
56_CD
SEC_NN
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
Evans_NN
Vaccines_NN
Limited_NN
46_CD
Remuneration_NOMZ
report_NN
56-63_CD
SFAS_NN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Exchange_NN
rate_NN
information_NOMZ
47_CD
Reserves_NN
35_CD
Standard_NN
Risk_NN
factors_NN
54-55_CD
UITF_NN
Urgent_NN
Issues_NN
Task_NN
Force_NN
Financial_NN
commitments_NOMZ
36-37_CD
UK_NN
GAAP_NN
United_NN
Kingdom_NN
generally_RB
accepted_VBD [PRIV]
Financial_NN
instruments_NOMZ
31-33_CD
Financial_NN
review_NN
14-15_CD
Sales_NN
and_PHC
marketing_GER
5_CD
accounting_GER
principles_NN
Fixed_VBN
asset_NN
investments_NOMZ
23_CD
,_,
28_CD
,_,
30_CD
Segmental_JJ
information_NOMZ
24_CD
US_FPP1
GAAP_NN
United_NN
States_NN
generally_RB
accepted_VBN [PRIV]
Foreign_NN
currencies_NN
24_CD
,_,
32_CD
,_,
47_CD
Selected_VBN
financial_JJ
information_NOMZ
48-49_CD
accounting_GER
principles_NN
CROSS-REFERENCE_NN
TO_PIN
FORM_NN
20-F_NN
This_DEMO
cross-reference_NN
to_PIN
Form_NN
20-F_NN
is_VPRT [PASS]
provided_VBN
to_TO
assist_VB
those_DEMP
who_WP
are_VPRT [BEMA]
more_EMPH
familiar_PRED
with_PIN
the_DT
contents_NN
and_PHC
layout_NN
of_PIN
an_DT
Annual_JJ
Report_NN
on_PIN
Form_NN
20-F_NN
._.
1a_CD
We_FPP1
have_VPRT [PEAS]
denoted_VBN
this_DEMO
Form_NN
20-F_JJ
information_NOMZ
by_PIN
using_VBG
this_DEMO
symbol_NN
,_,
where_RB
the_DT
number_NN
denotes_VPRT
the_DT
specific_JJ
item_NN
on_PIN
the_DT
cross-reference_NN
._.
The_DT
information_NOMZ
in_PIN
this_DEMO
document_NOMZ
that_DEMP
is_VPRT [PASS]
referred_VBN
to_PIN
in_PIN
the_DT
following_VBG
table_NN
shall_PRMD
be_VB [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [PASS]
filed_VBN
with_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
for_PIN
all_QUAN
purposes_NN
._.
Item_NN
Page_NN
Item_NN
Page_NN
Item_NN
Page_NN
1_CD
Identity_NOMZ
of_PIN
directors_NN
,_,
senior_JJ
management_NOMZ
and_PHC
advisers_NN
n_VPRT
a_DT
7_CD
Major_JJ
shareholders_NN
and_CC
related_VBN
party_NN
transactions_NOMZ
12_CD
Description_NOMZ
of_PIN
securities_NOMZ
other_JJ
than_PIN
equity_NOMZ
securities_NOMZ
n_VPRT
a_DT
a_DT
Major_JJ
shareholders_NN
64_CD
2Offer_JJ
statistics_NN
and_CC
expected_VBN [PRIV]
timetable_NN
n_NN
a_DT
b_NN
Related_VBN
party_NN
transactions_NOMZ
37_CD
13_CD
Defaults_NN
,_,
dividend_NN
arrears_NN
and_PHC
delinquencies_NN
none_INPR
c_NN
Interests_NN
of_PIN
experts_NN
and_PHC
counsel_NN
n_VPRT
a_DT
3Key_NN
Information_NOMZ
14_CD
Material_NN
modifications_NOMZ
to_PIN
the_DT
rights_NN
of_PIN
security_NOMZ
holders_NN
n_VPRT
a_DT
a_DT
Selected_VBN
financial_JJ
data_NN
48-49_CD
8_CD
Financial_NN
information_NOMZ
see_VPRT [PRIV]
Item_NN
17_CD
and_CC
use_NN
of_PIN
proceeds_NN
b_NN
Capitalisation_NOMZ
and_PHC
indebtedness_NOMZ
n_VPRT
a_DT
c_NN
Reasons_NN
for_PIN
the_DT
offer_NN
and_PHC
use_NN
of_PIN
proceeds_NN
n_VPRT
a_DT
9The_JJ
offer_NN
and_PHC
listing_GER
15_CD
Controls_NN
and_PHC
procedures_NN
53_CD
d_SYM
Risk_NN
factors_NN
54-55_CD
a_DT
The_DT
offer_NN
and_PHC
listing_GER
details_NN
65_CD
b_NN
Plan_NN
of_PIN
distribution_NOMZ
n_VPRT
a_DT
16_CD
Reserved_VBN
item_NN
n_NN
a_DT
4Information_NOMZ
on_PIN
the_DT
Company_NN
c_NN
Markets_NN
65_CD
a_DT
History_NN
and_PHC
development_NOMZ
of_PIN
the_DT
Company_NN
1-15_CD
,_,
67_CD
d_SYM
Selling_VBG
shareholders_NN
n_VPRT
a_DT
17_CD
Financial_NN
statements_NOMZ
b_NN
Business_NOMZ
overview_VBD
1-15_CD
,_,
24_CD
,_,
43-44_CD
,_,
54-55_CD
e_SYM
Dilution_NOMZ
n_VBD
a_DT
a_DT
Directors_NN
responsibilities_NOMZ
16_CD
c_NN
Organisational_NN
structure_NN
note_NN
14_CD
a_DT
28_CD
f_SYM
Expenses_NN
of_PIN
the_DT
issue_NN
n_VBD
a_DT
b_NN
Independent_NN
auditors_NN
report_VPRT [PUBV]
to_PIN
members_NN
of_PIN
Acambis_NN
plc_NN
16-17_CD
d_SYM
Property_NN
,_,
plants_NN
and_PHC
equipment_NOMZ
47_CD
c_NN
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
18_CD
10_CD
Additional_JJ
information_NOMZ
d_SYM
Group_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
18_CD
5_CD
Operating_GER
and_CC
financial_JJ
review_NN
and_PHC
prospects_NN
a_DT
Share_NN
capital_NN
n_VBD
a_DT
e_SYM
Group_NN
balance_NN
sheet_NN
19_CD
a_DT
Operating_GER
results_NN
14-15_CD
,_,
43_CD
b_NN
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
66_CD
f_SYM
Company_NN
balance_NN
sheet_NN
20_CD
b_NN
Liquidity_NOMZ
and_PHC
capital_NN
resources_NN
44_CD
c_NN
Material_NN
contracts_NN
44-46_CD
g_NN
Group_NN
cash_NN
flow_NN
statement_NOMZ
21_CD
c_NN
Research_NN
and_PHC
development_NOMZ
,_,
patents_NN
and_PHC
licences_NN
etc._FW
._.
14_CD
,_,
43_CD
,_,
44-46_CD
d_SYM
Exchange_NN
controls_VPRT
47_CD
h_NN
Notes_NN
to_PIN
Group_NN
financial_JJ
statements_NOMZ
22-49_JJ
d_SYM
Trend_NN
information_NOMZ
14-15_CD
,_,
43_CD
e_SYM
Taxation_NOMZ
46_CD
f_SYM
Dividends_NN
and_CC
paying_VBG
agents_NN
n_VPRT
a_DT
18_CD
Financial_NN
statements_NOMZ
see_VPRT [PRIV]
Item_NN
17_CD
6_CD
Directors_NN
,_,
senior_JJ
management_NOMZ
and_PHC
employees_NN
g_VPRT
Statement_NOMZ
by_PIN
experts_NN
n_VPRT
a_DT
a_DT
Directors_NN
and_CC
senior_JJ
management_NOMZ
50-51_CD
h_VPRT
Documents_NOMZ
on_PIN
display_NN
66_CD
19_CD
Exhibits_NN
n_VPRT
a_DT
b_NN
Compensation_NOMZ
56-63_CD
i_FPP1
Subsidiary_NN
information_NOMZ
n_VBD
a_DT
c_NN
Board_NN
practices_NN
52-53_JJ
d_SYM
Employees_NN
note_VPRT [PRIV]
8_CD
26_CD
11_CD
Quantitative_JJ
and_PHC
qualitative_JJ
disclosure_NN
about_IN
market_NN
risk_NN
e_SYM
Share_NN
ownership_NN
59-62_CD
Financial_NN
instruments_NOMZ
31-33_CD
69_CD
Acambis_NN
plc_NN
Peterhouse_NN
Technology_NN
Park_NN
100_CD
Fulbourn_NN
Road_NN
Cambridge_NN
CB1_NN
9PT_NN
UK_NN
Tel_NN
:_:
44_CD
0_CD
1223 275 300_CD
Fax_NN
:_:
44_CD
0_CD
1223 416 300_CD
E-mail_NN
:_:
acambis@acambis_NN
._.
